CD47 and diffuse large B-cell lymphoma: However, only two B-cell lines were presented as examples of susceptible SLAMF7-positive cells, with DLBCL being proposed as a suitable target for CD47 blocking therapy solely based on high SLAMF7 mRNA levels in a patient cohort.